FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hiroaki Mitsuya

Research Profile

Living Beings

HIV-1
HIV

Chemicals & Drugs

Physiology

Anatomy

Cell Line

Disorders

Concepts & Ideas

Occupations

Drug Design

Co-author Network

Publications

TOP 3
Masayuki Amano; Manabu Aoki; Joseph Richard Campbell; Debananda Das; Arun K Ghosh; Kalapala Venkateswara Rao; Pedro Miguel Salcedo-Gómez; Yasushi Tojo; Chun-Xiao Xu; Hiroaki Mitsuya
GRL-0519, a Novel Oxatricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants In Vitro.
Hiromichi Yuki; Motohiro Takeya; Hiro Tatetsu; Shikiko Ueno; Toshiki Watanabe; Koichi Akashi; Shinya Endo; Hiroyuki Hata; Tadafumi Iino; Yawara Kawano; Yoshihiro Komohara; Hiroaki Mitsuya; Hiroaki Niiro; Seiji Okada; Yutaka Okuno
PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
Manabu Aoki; Hiromi Aoki-Ogata; Matthew L Danish; Debananda Das; Kazuhiko Ide; Yasuhiro Koh; Masayuki Amano; Hiroaki Mitsuya
Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hiroaki Mitsuya (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Masayuki Amano; Manabu Aoki; Joseph Richard Campbell; Debananda Das; Arun K Ghosh; Kalapala Venkateswara Rao; Pedro Miguel Salcedo-Gómez; Yasushi Tojo; Chun-Xiao Xu; Hiroaki Mitsuya
GRL-0519, a Novel Oxatricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants In Vitro.
Antimicrobial agents and chemotherapy 2013;57(5):2036-46.
2013: Hiromichi Yuki; Motohiro Takeya; Hiro Tatetsu; Shikiko Ueno; Toshiki Watanabe; Koichi Akashi; Shinya Endo; Hiroyuki Hata; Tadafumi Iino; Yawara Kawano; Yoshihiro Komohara; Hiroaki Mitsuya; Hiroaki Niiro; Seiji Okada; Yutaka Okuno
PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
Blood 2013;121(6):962-70.
2012: Manabu Aoki; Hiromi Aoki-Ogata; Matthew L Danish; Debananda Das; Kazuhiko Ide; Yasuhiro Koh; Masayuki Amano; Hiroaki Mitsuya
Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.
Journal of virology 2012;86(24):13384-96.
2012: Yawara Kawano; Hiroaki Mitsuya; Yutaka Okuno; Akira Sakai; Naoko Wada; Hiroshi Yamasaki; Hiromichi Yuki; Shiho Fujiwara; Kenichi Iyama; Mikiko Izaki; Hiroyuki Hata
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
International journal of oncology 2012;41(3):876-84.
2012: Kenji Maeda; Debananda Das; Hirotomo Nakata; Hiroaki Mitsuya
CCR5 inhibitors: emergence, success, and challenges.
Expert opinion on emerging drugs 2012;17(2):135-45.
2012: Arun K Ghosh; Johnson Agniswamy; Masayuki Amano; Bruno D Chapsal; Melinda Steffey; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.
Bioorganic & medicinal chemistry letters 2012;22(6):2308-11.
2012: Arun K Ghosh; David D Anderson; Irene T Weber; Hiroaki Mitsuya
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
Angewandte Chemie (International ed. in English) 2012;51(8):1778-802.
2012: Yutaka Okuno; Hiro Tatetsu; Kisato Nosaka; Hiroaki Mitsuya
Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication.
Journal of clinical and experimental hematopathology : JCEH 2012;52(2):101-6.
2012: Yawara Kawano; Yoshitaka Kikukawa; Hiroaki Mitsuya; Yutaka Okuno; Shikiko Ueno; Hiromichi Yuki; Masahiro Abe; Kenichi Iyama; Hiroyuki Hata
TRAIL produced from multiple myeloma cells is associated with osteolytic markers.
Oncology reports 2012;27(1):39-44.
2012: Tanyaradzwa P Ndongwe; Yee Tsuey Ong; Michael A Parniak; Vinay K Pathak; Devendra K Rai; Emily M Ryan; Kamalendra Singh; Angela S Whatley; Yi-Min Zheng; Adeyemi O Adedeji; Donald H Burke; Krista A Delviks-Frankenberry; Shilei Ding; Atsuko Hachiya; Marc Johnson; Karen A Kirby; Ei-Ichi Kodama; Shan-Lu Liu; Bruno Marchand; Eleftherios Michailidis; Hiroaki Mitsuya; Stefan G Sarafianos
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.
Nucleic acids research 2012;40(1):345-59.
2011: Arun K Ghosh; Johnson Agniswamy; Masayuki Amano; Bruno D Chapsal; Garth L Parham; Melinda Steffey; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.
Journal of medicinal chemistry 2011;54(16):5890-901.
2011: Rena Nishizawa; Kenji Sagawa; Shiro Shibayama; Hideaki Tada; Yoshikazu Takaoka; Daikichi Fukushima; Katsuya Hisaichi; Kenji Maeda; Chiaki Minamoto; Masayuki Murota; Hisao Nakai; Toshihiko Nishiyama; Hiroaki Mitsuya
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.
Bioorganic & medicinal chemistry 2011;19(13):4028-42.
2011: Rena Nishizawa; Toshihiko Nishiyama; Katsuya Hisaichi; Chiaki Minamoto; Naoki Matsunaga; Yoshikazu Takaoka; Hisao Nakai; Stephen Jenkinson; Wieslaw M Kazmierski; Hideaki Tada; Kenji Sagawa; Shiro Shibayama; Daikichi Fukushima; Kenji Maeda; Hiroaki Mitsuya
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.
Bioorganic & medicinal chemistry letters 2011;21(4):1141-5.
2011: Takeru Nambu; Akinobu Hamada; Reiko Nakashima; Misato Yuki; Tatsuya Kawaguchi; Hiroaki Mitsuya; Hideyuki Saito
Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia.
Biological & pharmaceutical bulletin 2011;34(1):114-9.
2011: Eisaku Iwanaga; Tomoko Nanri; Hiroaki Mitsuya; Norio Asou
Mutation in the RNA binding protein TIS11D/ZFP36L2 is associated with the pathogenesis of acute leukemia.
International journal of oncology 2011;38(1):25-31.
2010: Takahiro Tsuji; Noritaka Takatsu; Kisato Nosaka; Toshiro Kawakita; Tomoko Nanri; Kentaro Horikawa; Hiroaki Mitsuya; Norio Asou
Extramedullary tumors presenting double vision in patients with t(8;21)(q22;q22) acute myeloid leukemia lacking mutations in the receptor tyrosine kinase genes KIT or FLT3.
Leukemia research 2010;34(12):e320-2.
2010: Arun K Ghosh; Chun-Xiao Xu; Kalapala Venkateswara Rao; Abigail Baldridge; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Manabu Aoki; Salcedo Gomez Pedro Miguel; Masayuki Amano; Hiroaki Mitsuya
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
ChemMedChem 2010;5(11):1850-4.
2010: Yawara Kawano; Tatsuya Nakama; Hiroyuki Hata; En Kimura; Natsue Maruyoshi; Makoto Uchino; Hiroaki Mitsuya
Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia.
Journal of the neurological sciences 2010;297(1-2):101-4.
2010: Kenji Maeda; Hiroaki Mitsuya
[Structure-guided molecular-targeting approach for development of AIDS therapeutics].
Nihon rinsho. Japanese journal of clinical medicine 2010;68(10):1889-95.
2010: Miki Nakamura; Yoshitaka Kikukawa; Motohiro Takeya; Hiroaki Mitsuya; Hiroyuki Hata
Clarithromycin attenuates autophagy in myeloma cells.
International journal of oncology 2010;37(4):815-20.
2010: Rena Nishizawa; Toshihiko Nishiyama; Katsuya Hisaichi; Keisuke Hirai; Hiromu Habashita; Yoshikazu Takaoka; Hideaki Tada; Kenji Sagawa; Shiro Shibayama; Kenji Maeda; Hiroaki Mitsuya; Hisao Nakai; Daikichi Fukushima; Masaaki Toda
Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.
Bioorganic & medicinal chemistry 2010;18(14):5208-23.
2010: Rie Yamada; Kentaro Horikawa; Sonoko Ishihara; Koyu Hoshino; Tatsuya Kawaguchi; Ken-ichi Iyama; Hiroaki Mitsuya; Norio Asou
Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug.
International journal of hematology 2010;91(4):711-5.
2010: Masayuki Amano; Hiroaki Mitsuya
[Recent and future development of anti-HIV agents].
Nihon rinsho. Japanese journal of clinical medicine 2010;68(3):395-400.
2010: Tomoko Nanri; Naokuni Uike; Toshiro Kawakita; Eisaku Iwanaga; Hiroaki Mitsuya; Norio Asou
A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation.
Genes, chromosomes & cancer 2010;49(3):237-41.
2010: Arun K Ghosh; Sandra Gemma; Elena Simoni; Abigail Baldridge; Eric Walters; Kazuhiko Ide; Yasushi Tojo; yasuhiro koh; Masayuki Amano; Hiroaki Mitsuya
Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.
Bioorganic & medicinal chemistry letters 2010;20(3):1241-6.
2010: Rena Nishizawa; Toshihiko Nishiyama; Katsuya Hisaichi; Keisuke Hirai; Hiromu Habashita; Yoshikazu Takaoka; Hideaki Tada; Kenji Sagawa; Shiro Shibayama; Kenji Maeda; Hiroaki Mitsuya; Hisao Nakai; Daikichi Fukushima; Masaaki Toda
Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles.
Bioorganic & medicinal chemistry letters 2010;20(2):763-6.
2010: Nobuyo Higashi-Kuwata; Masatoshi Jinnin; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Faith C Muchemwa; Yuji Yonemura; Yoshihiro Komohara; Motohiro Takeya; Hiroaki Mitsuya; Hironobu Ihn
Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis.
Arthritis research & therapy 2010;12(4):R128.
2010: Hirotomo Nakata; Michael Kruhlak; Wakako Kamata; Hiromi Ogata-Aoki; Jianfeng Li; Kenji Maeda; Arun K Ghosh; Hiroaki Mitsuya
Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
Antiviral therapy 2010;15(3):321-31.
2009: Arun K Ghosh; Sarang Kulkarni; David D Anderson; Lin Hong; Abigail Baldridge; Yuan-Fang Wang; Alexander A Chumanevich; Andrey Yu Kovalevsky; Yasushi Tojo; Masayuki Amano; yasuhiro koh; Jordan Tang; Irene T Weber; Hiroaki Mitsuya
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
Journal of medicinal chemistry 2009;52(23):7689-705.
2009: Debananda Das; yasuhiro koh; Yasushi Tojo; Arun K Ghosh; Hiroaki Mitsuya
Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.
Journal of chemical information and modeling 2009;49(12):2851-62.
2009: S Ueno; Hiro Tatetsu; Hiroyuki Hata; T Iino; H Niiro; K Akashi; Daniel G Tenen; Hiroaki Mitsuya; Yutaka Okuno
PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.
Oncogene 2009;28(46):4116-25.
2009: Shiho Fujiwara; Hirosada Miyake; Kisato Nosaka; Minoru Yoshida; Sonoko Ishihara; Kentaro Horikawa; Yuji Yonemura; Kenichi Iyama; Hiroaki Mitsuya; Norio Asou
Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia.
International journal of hematology 2009;90(4):471-5.
2009: Eisaku Iwanaga; Miki Nakamura; Tomoko Nanri; Toshiro Kawakita; Kentaro Horikawa; Hiroaki Mitsuya; Norio Asou
Acute promyelocytic leukemia harboring a STAT5B-RARA fusion gene and a G596V missense mutation in the STAT5B SH2 domain of the STAT5B-RARA.
European journal of haematology 2009;83(5):499-501.
2009: Shinichiro Hattori; Kazuhiko Ide; Hirotomo Nakata; Hideki Harada; Shinya Suzu; Noriyuki Ashida; Satoru Kohgo; Hiroyuki Hayakawa; Hiroaki Mitsuya; Seiji Okada
Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.
Antimicrobial agents and chemotherapy 2009;53(9):3887-93.
2009: Arun K Ghosh; Sofiya Leshchenko-Yashchuk; David D Anderson; Abigail Baldridge; Marcus Noetzel; Heather B Miller; Yunfeng Tie; Yuan-Fang Wang; yasuhiro koh; Irene T Weber; Hiroaki Mitsuya
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
Journal of medicinal chemistry 2009;52(13):3902-14.
2009: Manabu Aoki; David J Venzon; yasuhiro koh; Hiromi Aoki-Ogata; Toshikazu Miyakawa; Kazuhisa Yoshimura; Kenji Maeda; Hiroaki Mitsuya
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Journal of virology 2009;83(7):3059-68.
2009: Eisaku Iwanaga; Tomoko Nanri; Naofumi Matsuno; Toshiro Kawakita; Hiroaki Mitsuya; Norio Asou
A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.
Haematologica 2009;94(3):433-5.
2009: Tomoko Nanri; Eisaku Iwanaga; Satomi Fujie; Yasuhiro Yamada; Kentaro Horikawa; Hiroaki Mitsuya; Norio Asou
Micafungin-induced immune hemolysis attacks.
International journal of hematology 2009;89(2):139-41.
2009: yasuhiro koh; Debananda Das; Sofiya Leschenko; Hirotomo Nakata; Hiromi Ogata-Aoki; Masayuki Amano; Maki Nakayama; Arun K Ghosh; Hiroaki Mitsuya
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Antimicrobial agents and chemotherapy 2009;53(3):997-1006.
2009: Hiroyuki Hata; Kazuhiko Nishi; Wataru Oshihara; Jiro Arai; Kazuyuki Shimizu; Tetsuro Kawakita; Miki Nakamura; Hiroaki Mitsuya
Adsorption of Bence-Jones protein to polymethylmethacrylate membrane in primary amyloidosis.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2009;16(2):108-10.
2009: Hiro Tatetsu; Fumihiko Matsuno; Noritaka Takatsu; Hirosada Miyake; Koyu Hoshino; Kisato Nosaka; Kentaro Horikawa; Hiroyuki Hata; Hiroaki Mitsuya; Norio Asou
Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.
Leukemia research 2009;33(1):197-200.
2008: Yasuhiro Yamada; Kiyoharu Ito; Yuko Watanabe; Kisato Nosaka; Kentaro Horikawa; Michihiro Hidaka; Fumio Kawano; Yutaka Sasaki; Hiroaki Mitsuya; Norio Asou
Allogeneic bone marrow transplantation after L-asparaginase-induced pancreatitis in a patient with acute lymphoblastic leukemia.
Leukemia research 2008;32(12):1944-6.
2008: Arun K Ghosh; Bruno D Chapsal; Abigail Baldridge; Kazuhiko Ide; yasuhiro koh; Hiroaki Mitsuya
Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors.
Organic letters 2008;10(22):5135-8.
2008: Arun K Ghosh; Sandra Gemma; Jun Takayama; Abigail Baldridge; Sofiya Leshchenko-Yashchuk; Heather B Miller; Yuan-Fang Wang; Andrey Yu Kovalevsky; yasuhiro koh; Irene T Weber; Hiroaki Mitsuya
Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
Organic & biomolecular chemistry 2008;6(20):3703-13.
2008: Arun K Ghosh; Sandra Gemma; Abigail Baldridge; Yuan-Fang Wang; Andrey Yu Kovalevsky; yasuhiro koh; Irene T Weber; Hiroaki Mitsuya
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Journal of medicinal chemistry 2008;51(19):6021-33.
2008: Yoshitaka Kikukawa; Yutaka Okuno; Hiro Tatetsu; Miki Nakamura; Naoko Harada; Shikiko Ueno; Yorinori Kamizaki; Hiroaki Mitsuya; Hiroyuki Hata
Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid.
International journal of oncology 2008;33(4):807-14.
2008: Kenji Maeda; Debananda Das; Philip D Yin; Kiyoto Tsuchiya; Hiromi Ogata-Aoki; Hirotomo Nakata; Rachael B Norman; Lauren A Hackney; Yoshikazu Takaoka; Hiroaki Mitsuya
Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.
Journal of molecular biology 2008;381(4):956-74.
2008: Akinobu Hamada; Tristan Sissung; Douglas K Price; Romano Danesi; Cindy H Chau; Nima Sharifi; David Venzon; Kenji Maeda; Keisuke Nagao; Alex Sparreboom; Hiroaki Mitsuya; William L Dahut; William D Figg
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3312-8.
2008: Hirotomo Nakata; Seth M Steinberg; yasuhiro koh; Kenji Maeda; Yoshikazu Takaoka; Hirokazu Tamamura; Nobutaka Fujii; Hiroaki Mitsuya
Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
Antimicrobial agents and chemotherapy 2008;52(6):2111-9.
2008: Kentaro Horikawa; Hironori Kudo; Sonoko Ishihara; Toshikazu Miyakawa; Tatsuya Kawaguchi; Hiroaki Mitsuya
[Aspergillosis of masticator space including mandibular bone responding to itraconazole treatment in a diabetic adult: case report].
Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases 2008;82(3):220-3.
2008: Atsushi Kawamoto; Eiichi Kodama; Stefan G Sarafianos; Yasuko Sakagami; Satoru Kohgo; Kenji Kitano; Noriyuki Ashida; Yuko Iwai; Hiroyuki Hayakawa; Hirotomo Nakata; Hiroaki Mitsuya; Eddy Arnold; Masao Matsuoka
2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.
The international journal of biochemistry & cell biology 2008;40(11):2410-20.
2008: Miki Nakamura; Hiroyasu Esumi; Lu Jin; Hiroaki Mitsuya; Hiroyuki Hata
Induction of necrosis in human myeloma cells by kigamicin.
Anticancer research 2008;28(1A):37-43.
2008: Hiroaki Mitsuya; Kenji Maeda; Debananda Das; Arun K Ghosh
Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.
Advances in pharmacology (San Diego, Calif.) 2008;56():169-97.
2008: Arun K Ghosh; Bruno D Chapsal; Irene T Weber; Hiroaki Mitsuya
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Accounts of chemical research 2008;41(1):78-86.
2007: Arun K Ghosh; Zachary L Dawson; Hiroaki Mitsuya
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
Bioorganic & medicinal chemistry 2007;15(24):7576-80.
2007: yasuhiro koh; Shintaro Matsumi; Debananda Das; Masayuki Amano; David A Davis; Jianfeng Li; Sofiya Leschenko; Abigail Baldridge; Tatsuo Shioda; Robert Yarchoan; Arun K Ghosh; Hiroaki Mitsuya
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
The Journal of biological chemistry 2007;282(39):28709-20.
2007: Kenji Maeda; Hiroaki Mitsuya
Development of therapeutics for AIDS: structure-based molecular targeting.
Tuberculosis (Edinburgh, Scotland) 2007;87 Suppl 1():S31-4.
2007: Hirotomo Nakata; Masayuki Amano; yasuhiro koh; Eiichi Kodama; Guangwei Yang; Christopher M Bailey; Satoru Kohgo; Hiroyuki Hayakawa; Masao Matsuoka; Karen S Anderson; Yung-Chi Cheng; Hiroaki Mitsuya
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
Antimicrobial agents and chemotherapy 2007;51(8):2701-8.
2007: Shigeyoshi Harada; Rohan Hazra; Sadahiro Tamiya; Steven L Zeichner; Hiroaki Mitsuya
Emergence of human immunodeficiency virus type 1 variants containing the Q151M complex in children receiving long-term antiretroviral chemotherapy.
Antiviral research 2007;75(2):159-66.
2007: Norio Asou; Yoshiharu Izuno; Toshiya Okubo; Kazuhiko Ide; Hiroshi Ueno; Makoto Kawakita; Hiroaki Mitsuya; Hiroyuki Hata
Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.
International journal of hematology 2007;86(1):69-71.
2007: Hiro Tatetsu; Shikiko Ueno; Hiroyuki Hata; Yasuhiro Yamada; Motohiro Takeya; Hiroaki Mitsuya; Daniel G Tenen; Yutaka Okuno
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
Cancer research 2007;67(11):5328-36.
2007: Masayuki Amano; yasuhiro koh; Debananda Das; Jianfeng Li; Sofiya Leschenko; Yuan-Fang Wang; Peter I Boross; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Antimicrobial agents and chemotherapy 2007;51(6):2143-55.
2007: Michael S Mitchell; Ellen T Bodine; Shawn Hill; Gerald Princler; Patricia A Lloyd; Hiroaki Mitsuya; Masao Matsuoka; David Derse
Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples.
Journal of virology 2007;81(9):4422-8.
2007: Norio Asou; Masatoshi Yanagida; Liqun Huang; Masayuki Yamamoto; Shigesada Katsuya; Hiroaki Mitsuya; Yoshiaki Ito; Motomi Osato
Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia.
Blood 2007;109(9):4023-7.
2007: Rena Nishizawa; Toshihiko Nishiyama; Katsuya Hisaichi; Naoki Matsunaga; Chiaki Minamoto; Hiromu Habashita; Yoshikazu Takaoka; Masaaki Toda; Shiro Shibayama; Hideaki Tada; Kenji Sagawa; Daikichi Fukushima; Kenji Maeda; Hiroaki Mitsuya
Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.
Bioorganic & medicinal chemistry letters 2007;17(3):727-31.
2007: Hiroshi Ohrui; Satoru Kohgo; Hiroyuki Hayakawa; Eiichi Kodama; Masao Matsuoka; Tomohiro Nakata; Hiroaki Mitsuya
2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma.
Nucleosides, nucleotides & nucleic acids 2007;26(10-12):1543-6.
2006: Candan Depboylu; Lee E Eiden; Martin K-H Schäfer; Todd A Reinhart; Hiroaki Mitsuya; Thomas J Schall; Eberhard Weihe
Fractalkine expression in the rhesus monkey brain during lentivirus infection and its control by 6-chloro-2',3'-dideoxyguanosine.
Journal of neuropathology and experimental neurology 2006;65(12):1170-80.
2006: Paola Miyazato; Jun-ichirou Yasunaga; Yuko Taniguchi; Yoshio Koyanagi; Hiroaki Mitsuya; Masao Matsuoka
De novo human T-cell leukemia virus type 1 infection of human lymphocytes in NOD-SCID, common gamma-chain knockout mice.
Journal of virology 2006;80(21):10683-91.
2006: David A Davis; Cara A Brown; Kathleen E Singer; Victoria Wang; Joshua Kaufman; Stephen J Stahl; Paul T Wingfield; Kenji Maeda; Shigeyoshi Harada; Kazuhisa Yoshimura; Pope Kosalaraksa; Hiroaki Mitsuya; Robert Yarchoan
Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
Antiviral research 2006;72(2):89-99.
2006: Kazuhisa Yoshimura; Junji Shibata; Tetsuya Kimura; Akiko Honda; Yosuke Maeda; Atsushi Koito; Toshio Murakami; Hiroaki Mitsuya; Shuzo Matsushita
Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
AIDS (London, England) 2006;20(16):2065-73.
2006: Shaoman Zhou; Earl R Kern; Elizabeth Gullen; Yung-Chi Cheng; John C Drach; Sadahiro Tamiya; Hiroaki Mitsuya; Jiri Zemlicka
9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1.
Journal of medicinal chemistry 2006;49(20):6120-8.
2006: Hiroaki Mitsuya
[Progress in AIDS therapy].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2006;95(9):1845-50.
2006: Arun K Ghosh; Perali Ramu Sridhar; Nagaswamy Kumaragurubaran; yasuhiro koh; Irene T Weber; Hiroaki Mitsuya
Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.
ChemMedChem 2006;1(9):939-50.
2006: Arun K Ghosh; Perali Ramu Sridhar; Sofiya Leshchenko; Azhar K Hussain; Jianfeng Li; Andrey Yu Kovalevsky; Eric Walters; Joseph E Wedekind; Valerie Grum-Tokars; Debananda Das; yasuhiro koh; Kenji Maeda; Hiroyuki Gatanaga; Irene T Weber; Hiroaki Mitsuya
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
Journal of medicinal chemistry 2006;49(17):5252-61.
2006: P D Yin; D Das; Hiroaki Mitsuya
Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance.
Cellular and molecular life sciences : CMLS 2006;63(15):1706-24.
2006: Hiromu Habashita; Masaya Kokubo; Shin-ichi Hamano; Nobuyuki Hamanaka; Masaaki Toda; Shiro Shibayama; Hideaki Tada; Kenji Sagawa; Daikichi Fukushima; Kenji Maeda; Hiroaki Mitsuya
Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
Journal of medicinal chemistry 2006;49(14):4140-52.
2006: Kenji Maeda; Debananda Das; Hiromi Ogata-Aoki; Hirotomo Nakata; Toshikazu Miyakawa; Yasushi Tojo; Rachael Norman; Yoshikazu Takaoka; Jianping Ding; Gail Arnold; Eddy Arnold; Hiroaki Mitsuya
Structural and molecular interactions of CCR5 inhibitors with CCR5.
The Journal of biological chemistry 2006;281(18):12688-98.
2006: Hiro Tatetsu; Norio Asou; Miki Nakamura; Nobuyoshi Hanaoka; Fumihiko Matsuno; Kentaro Horikawa; Hiroaki Mitsuya
Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia.
American journal of hematology 2006;81(5):366-9.
2006: Arun K Ghosh; Gary Schiltz; Ramu Sridhar Perali; Sofiya Leshchenko; Stephanie Kay; Eric Walters; yasuhiro koh; Kenji Maeda; Hiroaki Mitsuya
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
Bioorganic & medicinal chemistry letters 2006;16(7):1869-73.
2006: Miki Nakamura; Tomomi Gotoh; Yutaka Okuno; Hiro Tatetsu; Takashi Sonoki; Shima Uneda; Masataka Mori; Hiroaki Mitsuya; Hiroyuki Hata
Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells.
Leukemia & lymphoma 2006;47(3):531-9.
2006: Nobuyoshi Hanaoka; Tatsuya Kawaguchi; Kentaro Horikawa; Shoichi Nagakura; Hiroaki Mitsuya; Hideki Nakakuma
Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP.
Blood 2006;107(3):1184-91.
2006: Hiroyuki Gatanaga; Debananda Das; Yasuhiro Suzuki; Damaris D Yeh; Khaja A Hussain; Arun K Ghosh; Hiroaki Mitsuya
Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop.
The Journal of biological chemistry 2006;281(2):1241-50.
2006: Hiroshi Ohrui; Satoru Kohgo; Hiroyuki Hayakawa; Eiichi Kodama; Masao Matsuoka; Tomohiro Nakata; Hiroaki Mitsuya
2'-Deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favorable toxic profiles and stability in plasma.
Nucleic acids symposium series (2004) 2006;(50):1-2.
2006: Yasuhiro Yamada; Eishi Nishimoto; Hiroaki Mitsuya; Yuji Yonemura
In vitro transdifferentiation of adult bone marrow Sca-1+ cKit- cells cocultured with fetal liver cells into hepatic-like cells without fusion.
Experimental hematology 2006;34(1):97-106.
2005: Yuji Yonemura; Hirosada Miyake; Norio Asou; Hiroaki Mitsuya
Long-term efficacy of pegylated recombinant human megakaryocyte growth and development factor in therapy of aplastic anemia.
International journal of hematology 2005;82(4):307-9.
2005: Takashi Sonoki; E Iwanaga; Hiroaki Mitsuya; Norio Asou
Insertion of microRNA-125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia.
Leukemia 2005;19(11):2009-10.
2005: Candan Depboylu; Martin K-H Schäfer; Wilhelm J Schwaeble; Todd A Reinhart; Hitomi Maeda; Hiroaki Mitsuya; Ruslan Damadzic; Dianne M Rausch; Lee E Eiden; Eberhard Weihe
Increase of C1q biosynthesis in brain microglia and macrophages during lentivirus infection in the rhesus macaque is sensitive to antiretroviral treatment with 6-chloro-2',3'-dideoxyguanosine.
Neurobiology of disease 2005;20(1):12-26.
2005: Takashi Sonoki; Eisaku Iwanaga; Hiroaki Mitsuya; Norio Asou
Ovarian relapse seven years after bone marrow transplantation for B-cell acute lymphoblastic leukemia: an unusual Krukenberg tumor.
American journal of hematology 2005;80(1):75-6.
2005: Tomoko Nanri; Naofumi Matsuno; Toshiro Kawakita; Hiroaki Mitsuya; Norio Asou
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation.
Leukemia 2005;19(9):1673-5.
2005: Tomoko Nanri; Naofumi Matsuno; Toshiro Kawakita; Hitoshi Suzushima; Fumio Kawano; Hiroaki Mitsuya; Norio Asou
Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
Leukemia 2005;19(8):1361-6.
2005: Hiro Tatetsu; Yutaka Okuno; Miki Nakamura; Fumihiko Matsuno; Takashi Sonoki; Izumi Taniguchi; Shima Uneda; Kazuo Umezawa; Hiroaki Mitsuya; Hiroyuki Hata
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Molecular cancer therapeutics 2005;4(7):1114-20.
2005: Shuzo Matsushita; Kazuhisa Yoshimura; Tetsuya Kimura; Asako Kamihira; Misao Takano; Kenichiro Eto; Takuma Shirasaka; Hiroaki Mitsuya; Shinichi Oka
Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term Combivir containing regimen.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2005;33(3):188-93.
2005: Arun K Ghosh; Lisa M Swanson; Hanna Cho; Sofiya Leshchenko; Khaja Azhar Hussain; Stephanie Kay; Eric Walters; yasuhiro koh; Hiroaki Mitsuya
Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
Journal of medicinal chemistry 2005;48(10):3576-85.
2005: Naofumi Matsuno; Koyu Hoshino; Tomoko Nanri; Toshiro Kawakita; Hitoshi Suzushima; Fumio Kawano; Hiroaki Mitsuya; Norio Asou
p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia.
Leukemia research 2005;29(5):557-64.
2005: Naofumi Matsuno; Tomoko Nanri; Toshiro Kawakita; Hiroaki Mitsuya; Norio Asou
A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia.
Leukemia 2005;19(3):480-1.
2005: Hirotomo Nakata; Kenji Maeda; Toshikazu Miyakawa; Shiro Shibayama; Masayoshi Matsuo; Yoshikazu Takaoka; Mamoru Ito; Yoshio Koyanagi; Hiroaki Mitsuya
Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
Journal of virology 2005;79(4):2087-96.
2004: Shaoman Zhou; Earl R Kern; Elizabeth Gullen; Yung-Chi Cheng; John C Drach; Shintaro Matsumi; Hiroaki Mitsuya; Jiri Zemlicka
(Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity.
Journal of medicinal chemistry 2004;47(27):6964-72.
2004: Maqbool A Siddiqui; Stephen H Hughes; Paul L Boyer; Hiroaki Mitsuya; Que N Van; Clifford George; Stefan G Sarafinanos; Victor E Marquez
A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides.
Journal of medicinal chemistry 2004;47(21):5041-8.
2004: Kenji Maeda; Hirotomo Nakata; Hiromi Ogata; yasuhiro koh; Toshikazu Miyakawa; Hiroaki Mitsuya
The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.
Current opinion in pharmacology 2004;4(5):447-52.
2004: Atsuko Hachiya; Hiroyuki Gatanaga; Eiichi Kodama; Mieko Ikeuchi; Masao Matsuoka; Shigeyoshi Harada; Hiroaki Mitsuya; Satoshi Kimura; Shinichi Oka
Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
Virology 2004;327(2):215-24.
2004: Jun-ichirou Yasunaga; Yuko Taniguchi; Kisato Nosaka; Mika Yoshida; Yutaka Satou; Tatsunori Sakai; Hiroaki Mitsuya; Masao Matsuoka
Identification of aberrantly methylated genes in association with adult T-cell leukemia.
Cancer research 2004;64(17):6002-9.
2004: Kenji Maeda; Hirotomo Nakata; yasuhiro koh; Toshikazu Miyakawa; Hiromi Ogata; Yoshikazu Takaoka; Shiro Shibayama; Kenji Sagawa; Daikichi Fukushima; Joseph Moravek; Yoshio Koyanagi; Hiroaki Mitsuya
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Journal of virology 2004;78(16):8654-62.
2004: Hiroyuki Hayakawa; Satoru Kohgo; Kenji Kitano; Noriyuki Ashida; Eiichi Kodama; Hiroaki Mitsuya; Hiroshi Ohrui
Potential of 4'-C-substituted nucleosides for the treatment of HIV-1.
Antiviral chemistry & chemotherapy 2004;15(4):169-87.
2004: Candan Depboylu; Todd A Reinhart; Osamu Takikawa; Yoshinori Imai; Hitomi Maeda; Hiroaki Mitsuya; Dianne M Rausch; Lee E Eiden; Eberhard Weihe
Brain virus burden and indoleamine-2,3-dioxygenase expression during lentiviral infection of rhesus monkey are concomitantly lowered by 6-chloro-2',3'-dideoxyguanosine.
The European journal of neuroscience 2004;19(11):2997-3005.
2004: Naofumi Matsuno; Koyu Hoshino; Tomoko Nanri; Toshiro Kawakita; Hiroaki Mitsuya; Norio Asou
Transcriptional repression of the p15 gene predicts the clinical outcome of acute myeloblastic leukemia with intermediate and adverse cytogenetics.
Leukemia 2004;18(6):1146-8.
2004: Kenji Kitano; Satoru Kohgo; Kohei Yamada; Shinji Sakata; Noriyuki Ashida; Hiroyuki Hayakawa; Daisuke Nameki; Eiichi Kodama; Masao Matsuoka; Hiroaki Mitsuya; Hiroshi Ohrui
Attempt to reduce cytotoxicity by synthesizing the L-enantiomer of 4'-C-ethynyl-2'-deoxypurine nucleosides as antiviral agents against HIV and HBV.
Antiviral chemistry & chemotherapy 2004;15(3):161-7.
2004: Reiko Yanada; yasuhiro koh; Nobuaki Nishimori; Akira Matsumura; Shingo Obika; Hiroaki Mitsuya; Nobutaka Fujii; Yoshiji Takemoto
Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitors.
The Journal of organic chemistry 2004;69(7):2417-22.
2004: Satoru Kohgo; Kohei Yamada; Kenji Kitano; Yuko Iwai; Shinji Sakata; Noriyuki Ashida; Hiroyuki Hayakawa; Daisuke Nameki; Eiichi Kodama; Masao Matsuoka; Hiroaki Mitsuya; Hiroshi Ohrui
Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides.
Nucleosides, nucleotides & nucleic acids 2004;23(4):671-90.
2003: Naofumi Matsuno; Motomi Osato; N Yamashita; Masatoshi Yanagida; Tomoko Nanri; T Fukushima; Toshiko Motoji; S Kusumoto; Masayuki Towatari; R Suzuki; T Naoe; K Nishii; Shigesada Katsuya; Ryuzo Ohno; Hiroaki Mitsuya; Yasuhiro Ito; Norio Asou
Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
Leukemia 2003;17(12):2492-9.
2003: Hiroaki Mitsuya
[Multi-drug resistant pathogens, positioning of various drugs, and their appropriate use: 1. Anti-HIV agents].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2003;92(11):2170-81.
2003: Ruifang Wang; Shigeyoshi Harada; Hiroaki Mitsuya; Jiri Zemlicka
Inhibition of human immunodeficiency virus reverse transcriptase by synadenol triphosphate and its E-isomer.
Journal of medicinal chemistry 2003;46(22):4799-802.
2003: yasuhiro koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter I Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
Antimicrobial agents and chemotherapy 2003;47(10):3123-9.
2003: Kazuhisa Yoshimura; Eiji Ido; Hisashi Akiyama; Tetsuya Kimura; Manabu Aoki; Hajime Suzuki; Hiroaki Mitsuya; Masanori Hayami; Shuzo Matsushita
The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV 89.6P.
Journal of virological methods 2003;112(1-2):121-8.
2003: Yongseok Choi; Clifford George; Maria J Comin; Joseph J Barchi; Hak-Sung Kim; Kenneth Alan Jacobson; Jan Balzarini; Hiroaki Mitsuya; Paul L Boyer; Stephen H Hughes; Victor E Marquez
A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
Journal of medicinal chemistry 2003;46(15):3292-9.
2003: Hiro Tatetsu; Norio Asou; Miki Nakamura; yasuhiro koh; Tetsuya Tajiri; Fumihiko Matsuno; Kentaro Horikawa; Yuji Yonemura; Hiroaki Mitsuya
[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine].
[Rinshō ketsueki] The Japanese journal of clinical hematology 2003;44(7):471-3.
2003: Richard F Little; Stefania Pittaluga; Nicole Grant; Seth M Steinberg; Mark F Kavlick; Hiroaki Mitsuya; Genoveffa Franchini; Martin Gutierrez; Mark Raffeld; Elaine S Jaffe; Gene Shearer; Robert Yarchoan; Wyndham H Wilson
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Blood 2003;101(12):4653-9.
2003: Shintaro Matsumi; Pope Kosalaraksa; Hsinyi Tsang; Mark F Kavlick; Shigeyoshi Harada; Hiroaki Mitsuya
Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants.
AIDS (London, England) 2003;17(8):1127-37.
2003: Satoru Kohgo; Kohei Yamada; Kenji Kitano; Shinji Sakata; Hiroyuki Hayakawa; Daisuke Nameki; Eiichi Kodama; Masao Matsuoka; Hiroaki Mitsuya; Hiroshi Ohrui
Synthesis of 4'-C-ethynyl and 4'-C-cyano purine nucleosides from natural nucleosides and their anti-HIV activity.
Nucleosides, nucleotides & nucleic acids 2003;22(5-8):887-9.
2003: Hirokazu Tamamura; yasuhiro koh; Satoshi Ueda; Yoshikazu Sasaki; Tomonori Yamasaki; Manabu Aoki; Kenji Maeda; Yoriko Watai; Hisashi Arikuni; Akira Otaka; Hiroaki Mitsuya; Nobutaka Fujii
Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
Journal of medicinal chemistry 2003;46(9):1764-8.
2003: Tatsuyoshi Kawamura; Hiroyuki Gatanaga; Debra L Borris; Mark Connors; Hiroaki Mitsuya; Andrew Blauvelt
Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(8):4260-6.
2003: Hiroaki Mitsuya
[HIV-1 infection and its treatment].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2003;92(3):502-7.
2003: Xinchao Chen; Shintaro Matsumi; Hiroaki Mitsuya; Jiri Zemlickal
Synthesis of (Z)-(2,3-bis-hydroxymethyl)methylenecyclopropane analogues of purine nucleosides.
Nucleosides, nucleotides & nucleic acids 2003;22(3):265-74.
2003: Shima Uneda; Hiroyuki Hata; Fumihiko Matsuno; Akitoshi Nagasaki; Naoko Harada; Yumi Mitsuya; Hiromitsu Matsuzaki; Hiroaki Mitsuya
A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model.
British journal of haematology 2003;120(3):396-404.
2003: Shima Uneda; Hiroyuki Hata; Fumihiko Matsuno; Naoko Harada; Yumi Mitsuya; Fumio Kawano; Hiroaki Mitsuya
Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM.
British journal of haematology 2003;120(1):53-5.
2002: Ruifang Wang; Thomas H Corbett; Yung-Chi Cheng; John C Drach; Earl R Kern; Hiroaki Mitsuya; Jiri Zemlicka
Tryptophanyl phosphoramidates as prodrugs of synadenol and its E-isomer: synthesis and biological activity.
Bioorganic & medicinal chemistry letters 2002;12(17):2467-70.
2002: Shoichi Nagakura; Sonoko Ishihara; Daniel E Dunn; Jun-ichi Nishimura; Tatsuya Kawaguchi; Kentaro Horikawa; Michihiro Hidaka; Tadashi Kagimoto; Nozomu Eto; Hiroaki Mitsuya; Taroh Kinoshita; Neal S Young; Hideki Nakakuma
Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro.
Blood 2002;100(3):1031-7.
2002: Koyu Hoshino; Norio Asou; Toshiya Okubo; Hitoshi Suzushima; Tetsuyuki Kiyokawa; Fumio Kawano; Hiroaki Mitsuya
The absence of the p15INK4B gene alterations in adult patients with precursor B-cell acute lymphoblastic leukaemia is a favourable prognostic factor.
British journal of haematology 2002;117(3):531-40.
2002: Hironori Kudo; Takako Matsuoka; Hiroaki Mitsuya; Yasuharu Nishimura; Sho Matsushita
Cross-linking HLA-DR molecules on Th1 cells induces anergy in association with increased level of cyclin-dependent kinase inhibitor p27(Kip1).
Immunology letters 2002;81(2):149-55.
2002: Hirotomo Nakata; Hiroaki Mitsuya
[The current status of structured treatment interruption].
Nihon rinsho. Japanese journal of clinical medicine 2002;60(4):807-12.
2002: Hiroaki Mitsuya
[Understanding of AIDS and its control].
Nihon rinsho. Japanese journal of clinical medicine 2002;60(4):641-5.
2002: Mutsunori Iga; Akihiko Okayama; Sherri O Stuver; Masao Matsuoka; Nancy Mueller; Manabu Aoki; Hiroaki Mitsuya; Nobuyoshi Tachibana; Hirohito Tsubouchi
Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses.
The Journal of infectious diseases 2002;185(5):691-5.
2002: Hiroyuki Gatanaga; Yasuhiro Suzuki; Hsinyi Tsang; Kazuhisa Yoshimura; Mark F Kavlick; Kunio Nagashima; Robert J Gorelick; Sek Mardy; Chun Tang; Michael F Summers; Hiroaki Mitsuya
Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.
The Journal of biological chemistry 2002;277(8):5952-61.
2002: Toshikazu Miyakawa; Kenshi Obaru; Kenji Maeda; Shigeyoshi Harada; Hiroaki Mitsuya
Identification of amino acid residues critical for LD78beta, a variant of human macrophage inflammatory protein-1alpha, binding to CCR5 and inhibition of R5 human immunodeficiency virus type 1 replication.
The Journal of biological chemistry 2002;277(7):4649-55.
2002: Kazuhisa Yoshimura; Ryohei Kato; Mark F Kavlick; Aline Nguyen; Victor Maroun; Kenji Maeda; Khaja A Hussain; Arun K Ghosh; Sergei V Gulnik; John W Erickson; Hiroaki Mitsuya
A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.
Journal of virology 2002;76(3):1349-58.
2002: David Egron; Christian Périgaud; Gilles Gosselin; Anne-Marie Aubertin; Hiroyuki Gatanaga; Hiroaki Mitsuya; Jiri Zemlicka; Jean-Louis Imbach
Increase of the adenallene anti-HIV activity in cell culture using its bis(tBuSATE) phosphotriester derivative.
Bioorganic & medicinal chemistry letters 2002;12(2):265-6.
2002: Kisato Nosaka; Takeshi Miyamoto; Tatsunori Sakai; Hiroaki Mitsuya; Toshio Suda; Masao Matsuoka
Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells.
Blood 2002;99(2):634-40.
2002: Kentaro Horikawa; Tatsuya Kawaguchi; Sonoko Ishihara; Shoichi Nagakura; Michihiro Hidaka; Tadashi Kagimoto; Hiroaki Mitsuya; Hideki Nakakuma
Frequent detection of T cells with mutations of the hypoxanthine-guanine phosphoribosyl transferase gene in patients with paroxysmal nocturnal hemoglobinuria.
Blood 2002;99(1):24-9.
2001: Hirotomo Nakata; Hiroaki Mitsuya
[Severe combined immunodeficiency disease and similar combined immunodeficiency disease].
Nihon rinsho. Japanese journal of clinical medicine 2001;59 Suppl 7():581-7.
2001: Y Suzuki; M Rahman; Hiroaki Mitsuya
Diverse transcriptional response of CD4(+) T cells to stromal cell-derived factor (SDF)-1: cell survival promotion and priming effects of SDF-1 on CD4(+) T cells.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(6):3064-73.
2001: Kenji Maeda; Kazuhisa Yoshimura; Shiro Shibayama; Hiromu Habashita; Hideaki Tada; Kenji Sagawa; Toshikazu Miyakawa; M Aoki; Daikichi Fukushima; Hiroaki Mitsuya
Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
The Journal of biological chemistry 2001;276(37):35194-200.
2001: Satoru Kohgo; Hiroaki Mitsuya; Hiroshi Ohrui
Synthesis of the L-enantiomer of 4'-C-ethynyl-2'-deoxycytidine.
Bioscience, biotechnology, and biochemistry 2001;65(8):1879-82.
2001: T Sakai; K Nosaka; Sadahiro Tamiya; S Koga; S Mita; M Uchino; Hiroaki Mitsuya; Masao Matsuoka
Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state.
Blood 2001;97(10):3177-83.
2001: Hiroshi Ohrui; Hiroaki Mitsuya
4'-C-substituted-2'-deoxynucleosides: a family of antiretroviral agents which are potent against drug-resistant HIV variants.
Current drug targets. Infectious disorders 2001;1(1):1-10.
2001: T Sakai; Masao Matsuoka; M Aoki; K Nosaka; Hiroaki Mitsuya
Missense mutation of the interleukin-12 receptor beta1 chain-encoding gene is associated with impaired immunity against Mycobacterium avium complex infection.
Blood 2001;97(9):2688-94.
2001: Eiichi Kodama; Satoru Kohgo; Kenji Kitano; H Machida; H Gatanaga; S Shigeta; Masao Matsuoka; Hiroshi Ohrui; Hiroaki Mitsuya
4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.
Antimicrobial agents and chemotherapy 2001;45(5):1539-46.
2000: Hiroshi Ohrui; Satoru Kohgo; Kenji Kitano; Shinji Sakata; Eiichi Kodama; K Yoshimura; Masao Matsuoka; S Shigeta; Hiroaki Mitsuya
Syntheses of 4'-C-ethynyl-beta-D-arabino- and 4'-C-ethynyl-2'-deoxy-beta-D-ribo-pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity.
Journal of medicinal chemistry 2000;43(23):4516-25.
2000: Andre A Pilon; Christophe Marchand; Mark F Kavlick; K Bajaj; J Owen; Hiroaki Mitsuya; Yves Pommier
Mutations in the HIV type 1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to zidovudine.
AIDS research and human retroviruses 2000;16(14):1417-22.
2000: L Mu; S G Sarafianos; Marc C Nicklaus; P Russ; Masood Siddiqui; Harry Ford; Hiroaki Mitsuya; R Le; EN Kodama; C Meier; T Knispel; L Anderson; Joseph J Barchi; Victor E Marquez
Interactions of conformationally biased north and south 2'-fluoro-2', 3'-dideoxynucleoside 5'-triphosphates with the active site of HIV-1 reverse transcriptase.
Biochemistry 2000;39(37):11205-15.
2000: Hiroaki Mitsuya
[Molecular mechanisms for the emergence of drug-resistant HIV-1].
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 2000;45(12):1899-908.
2000: F S Shah; Kenneth A Curr; Monica E Hamburgh; Michael A Parniak; Hiroaki Mitsuya; J G Arnez; Vinayaka R Prasad
Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase.
The Journal of biological chemistry 2000;275(35):27037-44.
2000: Sonoko Ishihara; Hideki Nakakuma; Tatsuya Kawaguchi; Shoichi Nagakura; Kentaro Horikawa; Michihiro Hidaka; Norio Asou; Hiroaki Mitsuya
Two cases showing clonal progression with full evolution from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome to myelodysplastic syndromes and leukemia.
International journal of hematology 2000;72(2):206-9.
2000: H Kudo; Satoru Senju; Hiroaki Mitsuya; Yasuharu Nishimura
Mouse and human GTPBP2, newly identified members of the GP-1 family of GTPase.
Biochemical and biophysical research communications 2000;272(2):456-65.
2000: K Li; Tatsuya Kawaguchi; Sonoko Ishihara; Kentaro Horikawa; Michihiro Hidaka; M Sakaguchi; R Tsuruzaki; M Kawakita; Tadashi Kagimoto; Hiroaki Mitsuya; Hideki Nakakuma
Rarity of microsatellite alterations in patients with paroxysmal nocturnal haemoglobinuria.
European journal of haematology 2000;64(6):430-2.
2000: Shizuko Sei; Quan-en Yang; D O'Neill; K Yoshimura; K Nagashima; Hiroaki Mitsuya
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
Journal of virology 2000;74(10):4621-33.
2000: Sonoko Ishihara; Kentaro Horikawa; Tatsuya Kawaguchi; L Ke; Michihiro Hidaka; Shoichi Nagakura; Hiroaki Mitsuya; F Sendo; Hideki Nakakuma
3H9, a monoclonal antibody capable of discriminating neutrophilic from basophilic and eosinophilic granulocytes.
European journal of haematology 2000;64(4):275-6.
2000: H Ito; Shuzo Matsushita; Y Tokano; H Nishimura; Yuetsu Tanaka; S Fujisao; Hiroaki Mitsuya; H Hashimoto; Yasuharu Nishimura
Analysis of T cell responses to the beta 2-glycoprotein I-derived peptide library in patients with anti-beta 2-glycoprotein I antibody-associated autoimmunity.
Human immunology 2000;61(4):366-77.
2000: K Nosaka; M Maeda; Sadahiro Tamiya; T Sakai; Hiroaki Mitsuya; Masao Matsuoka
Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia.
Cancer research 2000;60(4):1043-8.
2000: Judith Falloon; Stephen C Piscitelli; S Vogel; B Sadler; Hiroaki Mitsuya; Mark F Kavlick; Kazuhisa Yoshimura; M Rogers; S LaFon; D J Manion; H Clifford Lane; Henry Masur
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;30(2):313-8.
2000: EN Kodama; R P McCaffrey; K Yusa; Hiroaki Mitsuya
Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells.
Biochemical pharmacology 2000;59(3):273-81.
2000: Kenji Kitano; Shinji Sakata; Satoru Kohgo; Masao Matsuoka; Eiichi Kodama; Hiroaki Mitsuya; Hiroshi Ohrui
Synthesis of 4'-ethynyl-purine nucleosides possessing anti-HIV activity.
Nucleic acids symposium series 2000;(44):105-6.
2000: Naoko Harada; Akitoshi Nagasaki; Hiroyuki Hata; Hiromitsu Matsuzaki; Fumihiko Matsuno; Hiroaki Mitsuya
Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Acta haematologica 2000;103(3):144-51.
2000: WY Gao; David G Johns; Hiroaki Mitsuya
Potentiation of the anti-HIV activity of zalcitabine and lamivudine by a CTP synthase inhibitor, 3-deazauridine.
Nucleosides, nucleotides & nucleic acids 2000;19(1-2):371-7.
2000: Tatsuya Kawaguchi; S Koga; H Hongo; Y Komiyama; K Li; Sonoko Ishihara; Kentaro Horikawa; Michihiro Hidaka; Hiroaki Mitsuya; Hideki Nakakuma
A novel type of factor XI deficiency showing compound genetic abnormalities: a nonsense mutation and an impaired transcription.
International journal of hematology 2000;71(1):84-9.
2000: T Shimomura; Yuji Yonemura; T Miyazoe; Hirosada Miyake; T Kato; H Miyazaki; Hiroaki Mitsuya; Makoto Kawakita
Thrombopoietin stimulates murine lineage negative, Sca-1+, C-Kit+, CD34- cells: comparative study with stem cell factor or interleukin-3.
International journal of hematology 2000;71(1):33-9.
2000: Norio Asou; Hitoshi Suzushima; S Nishimura; Toshiya Okubo; H Yamasaki; Motomi Osato; Koyu Hoshino; Kiyoshi Takatsuki; Hiroaki Mitsuya
Long-term remission in an elderly patient with mantle cell leukemia treated with low-dose cyclophosphamide.
American journal of hematology 2000;63(1):35-7.
1999: M Fujiwara; E N Kodama; M Okamoto; K Tokuhisa; T Ide; Y Hanasaki; K Katsuura; H Takayama; N Aimi; Hiroaki Mitsuya; S Shigeta; K Konno; T Yokota; M Baba
Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217.
Antiviral chemistry & chemotherapy 1999;10(6):315-20.
1999: Kazuhisa Yoshimura; R Feldman; EN Kodama; Mark F Kavlick; YL Qiu; Jiri Zemlicka; Hiroaki Mitsuya
In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues.
Antimicrobial agents and chemotherapy 1999;43(10):2479-83.
1999: Naoko Harada; Hiroyuki Hata; Fumihiko Matsuno; Takashi Sonoki; N Kuribayashi; Hiromitsu Matsuzaki; Hiroaki Mitsuya
Absence of Kaposi's sarcoma-associated herpesvirus (KSHV) in bone marrow cells from Japanese myeloma patients.
Leukemia 1999;13(9):1465-6.
1999: Kazuhisa Yoshimura; Ryohei Kato; K Yusa; Mark F Kavlick; Victor Maroun; A Nguyen; Tsutomu Mimoto; T Ueno; Makoto Shintani; Judith Falloon; Henry Masur; Hideya Hayashi; J Erickson; Hiroaki Mitsuya
JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(15):8675-80.
1999: Pope Kosalaraksa; Mark F Kavlick; Victor Maroun; R Le; Hiroaki Mitsuya
Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay.
Journal of virology 1999;73(7):5356-63.
1999: H Uchida; EN Kodama; Kazuhisa Yoshimura; Y Maeda; Pope Kosalaraksa; Victor Maroun; YL Qiu; Jiri Zemlicka; Hiroaki Mitsuya
In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters.
Antimicrobial agents and chemotherapy 1999;43(6):1487-90.
1999: Takashi Sonoki; Hiromitsu Matsuzaki; Akitoshi Nagasaki; Hiroyuki Hata; Masahiro Yoshida; Masao Matsuoka; N Kuribayashi; T Kimura; Naoko Harada; Kiyoshi Takatsuki; Hiroaki Mitsuya; Masataka Mori
Detection of inducible nitric oxide synthase (iNOS) mRNA by RT-PCR in ATL patients and HTLV-I infected cell lines: clinical features and apoptosis by NOS inhibitor.
Leukemia 1999;13(5):713-8.
1999: Hiroaki Mitsuya
[Recent challenges and progress in AIDS therapy--emergence of drug resistant HIV-1 variants].
[Rinshō ketsueki] The Japanese journal of clinical hematology 1999;40(4):249-54.
1999: Charles S Rabkin; Q Yang; James J Goedert; G Nguyen; Hiroaki Mitsuya; Shizuko Sei
Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals.
Blood 1999;93(6):1838-42.
1999: M Okamoto; M Fujiwara; E Kodama; O Yamamoto; S Shigeta; Hiroaki Mitsuya; K Konno; T Yokota; M Baba
Inhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivative.
Antiviral chemistry & chemotherapy 1999;10(2):71-7.
1999: Takashi Sonoki; Hiroyuki Hata; N Kuribayashi; Masahiro Yoshida; Naoko Harada; Akitoshi Nagasaki; T Kimura; Fumihiko Matsuno; Hiroaki Mitsuya; Hiromitsu Matsuzaki
Expression of PRAD1/cyclin D1 in plasma cell malignancy: incidence and prognostic aspects.
British journal of haematology 1999;104(3):614-7.
1999: WY Gao; David G Johns; M Tanaka; Hiroaki Mitsuya
Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
Molecular pharmacology 1999;55(3):535-40.
1999: Rachel Humphrey; Kathleen M Wyvill; BY Nguyen; LE Shay; David R Kohler; Seth M Steinberg; T Ueno; T Fukasawa; M Shintani; Hideya Hayashi; Hiroaki Mitsuya; Robert Yarchoan
A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.
Antiviral research 1999;41(1):21-33.
1999: David A Davis; K Yusa; L A Gillim; Fonda M Newcomb; Hiroaki Mitsuya; Robert Yarchoan
Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions.
Journal of virology 1999;73(2):1156-64.
1999: Takashi Sonoki; Hiromitsu Matsuzaki; E Satterwhite; N Nakazawa; Hiroyuki Hata; Philip W Tucker; M Taniwaki; N Kuribayashi; Naoko Harada; Fumihiko Matsuno; Hiroaki Mitsuya
A plasma cell leukemia patient showing bialleic 14q translocations: t(2;14) and t(11;14).
Acta haematologica 1999;101(4):197-201.
1998: Takashi Sonoki; N Nakazawa; Hiroyuki Hata; M Taniwaki; Akitoshi Nagasaki; M Seto; Masahiro Yoshida; N Kuribayashi; T Kimura; Naoko Harada; Hiroaki Mitsuya; Hiromitsu Matsuzaki
Amplification and overexpression of the PRAD1/Cyclin D1 gene in a multiple myeloma cell line.
International journal of hematology 1998;68(4):459-61.
1998: Naoko Harada; Hiroyuki Hata; Masahiro Yoshida; T Soniki; Akitoshi Nagasaki; N Kuribayashi; T Kimura; Hiromitsu Matsuzaki; Hiroaki Mitsuya
Expression of Bcl-2 family of proteins in fresh myeloma cells.
Leukemia 1998;12(11):1817-20.
1998: JS Roth; Harry Ford; M Tanaka; Hiroaki Mitsuya; James A Kelley
Determination of 2'-beta-fluoro-2',3'-dideoxyadenosine, an experimental anti-AIDS drug, in human plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):199-210.
1998: WY Gao; Bing-Sen Zhou; David G Johns; Hiroaki Mitsuya; Yun Yen
Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.
Biochemical pharmacology 1998;56(1):105-12.
1998: BU Mueller; B D Anderson; M Q Farley; R Murphy; J Zuckerman; Paul F Jarosinski; Karen Godwin; Cynthia McCully; Hiroaki Mitsuya; PA Pizzo; FRANK BALIS
Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.
Antimicrobial agents and chemotherapy 1998;42(7):1815-8.
1998: Mark F Kavlick; Kathleen M Wyvill; Robert Yarchoan; Hiroaki Mitsuya
Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
The Journal of infectious diseases 1998;177(6):1506-13.
1998: Y Maeda; DJ Venzon; Hiroaki Mitsuya
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.
The Journal of infectious diseases 1998;177(5):1207-13.
1998: Lisa F Rezende; Kenneth A Curr; T Ueno; Hiroaki Mitsuya; Vinayaka R Prasad
The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity.
Journal of virology 1998;72(4):2890-5.
1998: Kenshi Obaru; Hiroaki Mitsuya
[Anti-HIV drugs and drug delivery system].
Nihon rinsho. Japanese journal of clinical medicine 1998;56(3):769-75.
1997: Hiroaki Mitsuya
[Chemotherapy of AIDS--recent progress].
Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology 1997;20(6):465-70.
1997: K Yusa; Mark F Kavlick; Pope Kosalaraksa; Hiroaki Mitsuya
HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.
Antiviral research 1997;36(3):179-89.
1997: H Uchida; Y Maeda; Hiroaki Mitsuya
HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
Antiviral research 1997;36(2):107-13.
1997: H Winter; Y Maeda; H Uchida; Hiroaki Mitsuya; Jiri Zemlicka
Phosphodiester amidates of unsaturated nucleoside analogues: synthesis and anti-HIV activity.
Journal of medicinal chemistry 1997;40(14):2191-5.
1997: M Tanaka; Ranga Srinivas; T Ueno; Mark F Kavlick; F K Hui; Arnold Fridland; JS Driscoll; Hiroaki Mitsuya
In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.
Antimicrobial agents and chemotherapy 1997;41(6):1313-8.
1997: Rachel Humphrey; Asa Ohagen; David A Davis; T Fukazawa; Hideya Hayashi; Stefan Höglund; Hiroaki Mitsuya; Robert Yarchoan
Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
Antimicrobial agents and chemotherapy 1997;41(5):1017-23.
1997: Hiroaki Mitsuya
Telling the truth to cancer patients and patients with HIV-1 infection in Japan.
Annals of the New York Academy of Sciences 1997;809():279-89.
1997: T Ueno; Hiroaki Mitsuya
Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay.
Biochemistry 1997;36(5):1092-9.
1997: Pim Brouwers; M Hendricks; JA Lietzau; James M Pluda; Hiroaki Mitsuya; S Broder; Robert Yarchoan
Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens.
AIDS (London, England) 1997;11(1):59-66.
1996: A Foli; K M Sogocio; B Anderson; Mark F Kavlick; MW Saville; Mark A Wainberg; Z Gu; Julie M Cherrington; Hiroaki Mitsuya; Robert Yarchoan
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Antiviral research 1996;32(2):91-8.
1996: H Winter; Y Maeda; Hiroaki Mitsuya; Jiri Zemlicka
Phosphodiester amidates of allenic nucleoside analogues: anti-HIV activity and possible mechanism of action.
Journal of medicinal chemistry 1996;39(17):3300-6.
1996: G S Ahluwalia; WY Gao; Hiroaki Mitsuya; David G Johns
2',3'-Didehydro-3'-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis.
Molecular pharmacology 1996;50(1):160-5.
1996: J S Driscoll; Masood Siddiqui; Harry Ford; James A Kelley; JS Roth; Hiroaki Mitsuya; M Tanaka; Victor E Marquez
Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.
Journal of medicinal chemistry 1996;39(8):1619-25.
1995: T Shirasaka; S Chokekijchai; A Yamada; G Gosselin; J L Imbach; Hiroaki Mitsuya
Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells.
Antimicrobial agents and chemotherapy 1995;39(11):2555-9.
1995: T Ueno; T Shirasaka; Hiroaki Mitsuya
Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates.
The Journal of biological chemistry 1995;270(40):23605-11.
1995: Mark F Kavlick; T Shirasaka; Eiji Kojima; James M Pluda; F Hui; Robert Yarchoan; Hiroaki Mitsuya
Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
Antiviral research 1995;28(2):133-46.
1995: S Chokekijchai; T Shirasaka; John N Weinstein; Hiroaki Mitsuya
In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
Antiviral research 1995;28(1):25-38.
1995: WY Gao; David G Johns; S Chokekuchai; Hiroaki Mitsuya
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(18):8333-7.
1995: WY Gao; Hiroaki Mitsuya; J S Driscoll; David G Johns
Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2'-beta-fluoro-2',3'-dideoxyadenosine in peripheral blood mononuclear cells.
Biochemical pharmacology 1995;50(2):274-6.
1995: Eric Baldwin; TN Bhat; Sergei V Gulnik; B Liu; Igor A Topol; Y Kiso; Tsutomu Mimoto; Hiroaki Mitsuya; John W Erickson
Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
Structure (London, England : 1993) 1995;3(6):581-90.
1995: R N Husson; Y Lan; Eiji Kojima; David Venzon; Hiroaki Mitsuya; Kenneth McIntosh
Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype.
The Journal of pediatrics 1995;126(6):865-71.
1995: Mary E Hawkins; Hiroaki Mitsuya; C M McCully; K S Godwin; K Murakami; David G Poplack; FRANK BALIS
Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys.
Antimicrobial agents and chemotherapy 1995;39(6):1259-64.
1995: B Y Nguyen; Robert Yarchoan; Kathleen M Wyvill; D J Venzon; James M Pluda; Hiroaki Mitsuya; S Broder
Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection.
The Journal of infectious diseases 1995;171(5):1180-9.
1995: Eiji Kojima; T Shirasaka; Bradley D Anderson; S Chokekijchai; Seth M Steinberg; S Broder; Robert Yarchoan; Hiroaki Mitsuya
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
The Journal of infectious diseases 1995;171(5):1152-8.
1995: B C Jones; J V Silverton; C Simons; S Megati; H Nishimura; Y Maeda; Hiroaki Mitsuya; Jiri Zemlicka
Synthesis, absolute configuration, and enantioselectivity of antiretroviral effect of (R)-(-)- and (S)-(+)-cytallene. Lipase-catalyzed enantioselective acylations of (+/-)-N4-acylcytallenes.
Journal of medicinal chemistry 1995;38(8):1397-405.
1995: Harry Ford; Masood Siddiqui; J S Driscoll; Victor E Marquez; James A Kelley; Hiroaki Mitsuya; T Shirasaka
Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-Halo and 6-alkoxy prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.
Journal of medicinal chemistry 1995;38(7):1189-95.
1995: Z Q Xu; YL Qiu; S Chokekijchai; Hiroaki Mitsuya; Jiri Zemlicka
Unsaturated acyclic analogues of 2'-deoxyadenosine and thymidine containing fluorine: synthesis and biological activity.
Journal of medicinal chemistry 1995;38(6):875-82.
1995: M C O'Brien; T Ueno; N Jahan; Maria Zajac-Kaye; Hiroaki Mitsuya
HIV-1 expression induced by anti-cancer agents in latently HIV-1-infected ACH2 cells.
Biochemical and biophysical research communications 1995;207(3):903-9.
1995: Eric Baldwin; TN Bhat; Sergei V Gulnik; B Liu; Y Kiso; Hiroaki Mitsuya; John W Erickson
Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine.
Advances in experimental medicine and biology 1995;362():445-9.
1994: Bradley D Anderson; T Shirasaka; Eiji Kojima; Robert Yarchoan; Hiroaki Mitsuya
Identification of drug-related genotypic changes in HIV-1 from serum using the selective polymerase chain reaction.
Antiviral research 1994;25(3-4):245-58.
1994: G S Ahluwalia; D A Cooney; T Shirasaka; Hiroaki Mitsuya; J S Driscoll; David G Johns
Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'-beta-fluoro-2',3'-dideoxyadenosine.
Molecular pharmacology 1994;46(5):1002-8.
1994: WY Gao; David G Johns; Hiroaki Mitsuya
Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.
Molecular pharmacology 1994;46(4):767-72.
1994: WY Gao; David G Johns; Hiroaki Mitsuya
Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2',3'-dideoxynucleosides.
Analytical biochemistry 1994;222(1):116-22.
1994: J B Rodriguez; Victor E Marquez; Marc C Nicklaus; Hiroaki Mitsuya; Joseph J Barchi
Conformationally locked nucleoside analogues. Synthesis of dideoxycarbocyclic nucleoside analogues structurally related to neplanocin C.
Journal of medicinal chemistry 1994;37(20):3389-99.
1994: Shizuko Sei; D E Kleiner; Jeffrey B Kopp; R Chandra; Paul Klotman; Robert Yarchoan; PA Pizzo; Hiroaki Mitsuya
Quantitative analysis of viral burden in tissues from adults and children with symptomatic human immunodeficiency virus type 1 infection assessed by polymerase chain reaction.
The Journal of infectious diseases 1994;170(2):325-33.
1994: S Kageyama; D T Hoekzema; Y Murakawa; Eiji Kojima; T Shirasaka; Dale J Kempf; Daniel W Norbeck; J Erickson; Hiroaki Mitsuya
A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro.
AIDS research and human retroviruses 1994;10(6):735-43.
1994: S Kageyama; Bradley D Anderson; B L Hoesterey; Hideya Hayashi; Y Kiso; K P Flora; Hiroaki Mitsuya
Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins.
Antimicrobial agents and chemotherapy 1994;38(5):1107-11.
1994: WY Gao; Riad Agbaria; J S Driscoll; Hiroaki Mitsuya
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.
The Journal of biological chemistry 1994;269(17):12633-8.
1994: Robert Yarchoan; J A Lietzau; B Y Nguyen; Otis W Brawley; James M Pluda; MW Saville; Kathleen M Wyvill; Seth M Steinberg; Riad Agbaria; Hiroaki Mitsuya
A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.
The Journal of infectious diseases 1994;169(1):9-17.
1993: Eiji Kojima; T Shirasaka; B Anderson; S Chokekijchai; Shizuko Sei; Robert Yarchoan; Hiroaki Mitsuya
Monitoring the activity of antiviral therapy for HIV infection using a polymerase chain reaction method coupled with reverse transcription.
AIDS (London, England) 1993;7 Suppl 2():S101-5.
1993: David G Johns; G S Ahluwalia; D A Cooney; Hiroaki Mitsuya; J S Driscoll
Enhanced stimulation by ribavirin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of purine 2'-beta-fluoro-2',3'-dideoxynucleosides.
Molecular pharmacology 1993;44(3):519-23.
1993: R N Husson; T Shirasaka; K M Butler; PA Pizzo; Hiroaki Mitsuya
High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
The Journal of pediatrics 1993;123(1):9-16.
1993: Robert Yarchoan; Hiroaki Mitsuya; S Broder
Challenges in the therapy of HIV infection.
Immunology today 1993;14(6):303-9.
1993: WY Gao; T Shirasaka; David G Johns; S Broder; Hiroaki Mitsuya
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
The Journal of clinical investigation 1993;91(5):2326-33.
1993: Robert Yarchoan; Hiroaki Mitsuya; S Broder
Challenges in the therapy of HIV infection.
Trends in pharmacological sciences 1993;14(5):196-202.
1993: G Ahluwalia; D A Cooney; N R Hartman; Hiroaki Mitsuya; Robert Yarchoan; Arnold Fridland; S Broder; David G Johns
Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.
Drug metabolism and disposition: the biological fate of chemicals 1993;21(2):369-76.
1993: T Shirasaka; Robert Yarchoan; M C O'Brien; R N Husson; Bradley D Anderson; Eiji Kojima; T Shimada; S Broder; Hiroaki Mitsuya
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(2):562-6.
1992: S Megati; Z Goren; J V Silverton; J Orlina; H Nishimura; T Shirasaki; Hiroaki Mitsuya; Jiri Zemlicka
(R)-(-)- and (S)-(+)-adenallene: synthesis, absolute configuration, enantioselectivity of antiretroviral effect, and enzymic deamination.
Journal of medicinal chemistry 1992;35(22):4098-104.
1992: K Kelly; P Davis; Hiroaki Mitsuya; S Irving; J Wright; R Grassmann; Bernhard Fleckenstein; Y Wano; Warner Greene; Ulrich Siebenlist
A high proportion of early response genes are constitutively activated in T cells by HTLV-I.
Oncogene 1992;7(8):1463-70.
1992: S Aoki-Sei; Robert Yarchoan; S Kageyama; D T Hoekzema; James M Pluda; Kathleen M Wyvill; S Broder; Hiroaki Mitsuya
Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction.
AIDS research and human retroviruses 1992;8(7):1263-70.
1992: Masood Siddiqui; J S Driscoll; Victor E Marquez; JS Roth; T Shirasaka; Hiroaki Mitsuya; Joseph J Barchi; James A Kelley
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
Journal of medicinal chemistry 1992;35(12):2195-201.
1992: Robert Yarchoan; Hiroaki Mitsuya; S Broder
The immunology of HIV infection: implications for therapy.
AIDS research and human retroviruses 1992;8(6):1023-31.
1992: S Kageyama; John N Weinstein; T Shirasaka; Dale J Kempf; Daniel W Norbeck; Jacob J Plattner; J Erickson; Hiroaki Mitsuya
In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations.
Antimicrobial agents and chemotherapy 1992;36(5):926-33.
1991: S Aoki-Sei; M C O'Brien; Harry Ford; H Fujii; D A Gilbert; D A Cooney; David G Johns; S Broder; Hiroaki Mitsuya
In vitro inhibition of hepatitis B virus replication by 2',3'-dideoxyguanosine, 2',3'-dideoxyinosine, and 3'-azido-2',3'-dideoxythymidine in 2.2.15 (PR) cells.
The Journal of infectious diseases 1991;164(5):843-51.
1991: Hiroaki Mitsuya
[Inhibitors of HIV-1 reverse transcriptase and protease as chemotherapeutics for AIDS].
Nihon rinsho. Japanese journal of clinical medicine 1991;49(9):2062-9.
1991: Robert Yarchoan; James M Pluda; Carlo Federico Perno; Hiroaki Mitsuya; S Broder
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future.
Blood 1991;78(4):859-84.
1991: Hiroaki Mitsuya; Robert Yarchoan; S Kageyama; S Broder
Targeted therapy of human immunodeficiency virus-related disease.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1991;5(10):2369-81.
1991: N R Hartman; G S Ahluwalia; D A Cooney; Hiroaki Mitsuya; S Kageyama; Arnold Fridland; S Broder; David G Johns
Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.
Molecular pharmacology 1991;40(1):118-24.
1991: Joseph J Barchi; Victor E Marquez; J S Driscoll; Harry Ford; Hiroaki Mitsuya; T Shirasaka; S Aoki; James A Kelley
Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.
Journal of medicinal chemistry 1991;34(5):1647-55.
1991: K Murakami; T Shirasaka; H Yoshioka; Eiji Kojima; S Aoki; Harry Ford; J S Driscoll; James A Kelley; Hiroaki Mitsuya
Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides.
Journal of medicinal chemistry 1991;34(5):1606-12.
1991: James M Pluda; Hiroaki Mitsuya; Robert Yarchoan
Hematologic effects of AIDS therapies.
Hematology/oncology clinics of North America 1991;5(2):229-48.
1991: C K Tseng; Victor E Marquez; GW Milne; R J Wysocki; Hiroaki Mitsuya; T Shirasaki; J S Driscoll
A ring-enlarged oxetanocin A analogue as an inhibitor of HIV infectivity.
Journal of medicinal chemistry 1991;34(1):343-9.
1991: L L Bondoc; Brian L Robbins; G S Ahluwalia; Hiroaki Mitsuya; David G Johns; Arnold Fridland
Modulation of metabolism and anti-HIV-1 activity of purine 2',3'-dideoxynucleosides by IMP dehydrogenase inhibitors.
Advances in experimental medicine and biology 1991;309A():49-53.
1991: Eiji Kojima; T Shirasaka; M Machida; H Yoshioka; K Murakami; Hiroaki Mitsuya
Synthesis and structure-activity relationships of 2',3'-dideoxypurine nucleosides as potential antiretroviral agents.
Nucleic acids symposium series 1991;(25):91-2.
1990: T Shirasaka; K Murakami; Harry Ford; James A Kelley; H Yoshioka; Eiji Kojima; S Aoki; S Broder; Hiroaki Mitsuya
Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(23):9426-30.
1990: S Aoki; Robert Yarchoan; R V Thomas; James M Pluda; K Marczyk; S Broder; Hiroaki Mitsuya
Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI).
AIDS research and human retroviruses 1990;6(11):1331-9.
1990: S Broder; Hiroaki Mitsuya; Robert Yarchoan; G N Pavlakis
NIH conference. Antiretroviral therapy in AIDS.
Annals of internal medicine 1990;113(8):604-18.
1990: G Ahluwalia; D A Cooney; L L Bondoc; M J Currens; Harry Ford; David G Johns; Hiroaki Mitsuya; Arnold Fridland
Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2' ,3'-dideoxyguanosine.
Biochemical and biophysical research communications 1990;171(3):1297-303.
1990: Hiroaki Mitsuya; Robert Yarchoan; S Broder
Molecular targets for AIDS therapy.
Science (New York, N.Y.) 1990;249(4976):1533-44.
1990: T Shiraska; Robert Yarchoan; Hiroaki Mitsuya
[Antiviral chemotherapy for AIDS: dideoxynucleosides and clinical application].
Nihon rinsho. Japanese journal of clinical medicine 1990;48(9):2141-50.
1990: Robert Yarchoan; James M Pluda; R V Thomas; Hiroaki Mitsuya; Pim Brouwers; Kathleen M Wyvill; N Hartman; David G Johns; S Broder
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.
Lancet 1990;336(8714):526-9.
1990: Robert Yarchoan; Hiroaki Mitsuya; S Broder
Immunologic issues in anti-retroviral therapy.
Immunology today 1990;11(9):327-33.
1990: Robert Yarchoan; Hiroaki Mitsuya; James M Pluda; K S Marczyk; R V Thomas; N R Hartman; Pim Brouwers; Carlo Federico Perno; J P Allain; David G Johns
The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.
Reviews of infectious diseases 1990;12 Suppl 5():S522-33.
1990: Hiroaki Mitsuya; Robert Yarchoan; S Hayashi; S Broder
Antiviral therapy against HIV infection.
Journal of the American Academy of Dermatology 1990;22(6 Pt 2):1282-94.
1990: N R Hartman; David G Johns; Hiroaki Mitsuya
Pharmacokinetic analysis of dextran sulfate in rats as pertains to its clinical usefulness for therapy of HIV infection.
AIDS research and human retroviruses 1990;6(6):805-12.
1990: J J Wright; K C Gunter; Hiroaki Mitsuya; S G Irving; K Kelly; Ulrich Siebenlist
Expression of a zinc finger gene in HTLV-I- and HTLV-II-transformed cells.
Science (New York, N.Y.) 1990;248(4955):588-91.
1990: R Masood; G S Ahluwalia; D A Cooney; Arnold Fridland; Victor E Marquez; J S Driscoll; Z Hao; Hiroaki Mitsuya; Carlo Federico Perno; S Broder
2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine.
Molecular pharmacology 1990;37(4):590-6.
1990: Victor E Marquez; C K Tseng; Hiroaki Mitsuya; S Aoki; James A Kelley; Harry Ford; JS Roth; S Broder; David G Johns; J S Driscoll
Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV.
Journal of medicinal chemistry 1990;33(3):978-85.
1990: S Hayashi; Daniel W Norbeck; W Rosenbrook; R L Fine; M Matsukura; Jacob J Plattner; S Broder; Hiroaki Mitsuya
Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro.
Antimicrobial agents and chemotherapy 1990;34(2):287-94.
1990: Robert Yarchoan; Hiroaki Mitsuya; S Broder
Strategies for the combination therapy of HIV infection.
Journal of acquired immune deficiency syndromes 1990;3 Suppl 2():S99-103.
1990: Robert Yarchoan; James M Pluda; Carlo Federico Perno; Hiroaki Mitsuya; R V Thomas; Kathleen M Wyvill; S Broder
Initial clinical experience with dideoxynucleosides as single agents and in combination therapy.
Annals of the New York Academy of Sciences 1990;616():328-43.
1990: S Hayashi; R L Fine; T C Chou; M J Currens; S Broder; Hiroaki Mitsuya
In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors.
Antimicrobial agents and chemotherapy 1990;34(1):82-8.
1989: Robert Yarchoan; Hiroaki Mitsuya; Charles E Myers; S Broder
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.
The New England journal of medicine 1989;321(11):726-38.
1989: S J Lee; W Hu; A G Fisher; D J Looney; Vivian Kao; Hiroaki Mitsuya; L Ratner; F Wong-Staal
Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity.
AIDS research and human retroviruses 1989;5(4):441-9.
1989: Robert Yarchoan; Hiroaki Mitsuya; S Broder
Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection.
The American journal of medicine 1989;87(2):191-200.
1989: Robert Yarchoan; Hiroaki Mitsuya; R V Thomas; James M Pluda; N R Hartman; Carlo Federico Perno; K S Marczyk; J P Allain; David G Johns; S Broder
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.
Science (New York, N.Y.) 1989;245(4916):412-5.
1989: Donald B Kohn; Hiroaki Mitsuya; M Ballow; J E Selegue; J Barankiewicz; A Cohen; E Gelfand; W French Anderson; R. Michael Blaese
Establishment and characterization of adenosine deaminase-deficient human T cell lines.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(11):3971-7.
1989: M Matsukura; G Zon; K Shinozuka; M Robert-Guroff; T Shimada; Cy A Stein; Hiroaki Mitsuya; F Wong-Staal; J S Cohen; S Broder
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(11):4244-8.
1989: Carlo Federico Perno; Robert Yarchoan; D A Cooney; N R Hartman; D S Webb; Z Hao; Hiroaki Mitsuya; David G Johns; S Broder
Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine.
The Journal of experimental medicine 1989;169(3):933-51.
1988: M Matsukura; G Zon; K Shinozuka; Cy A Stein; Hiroaki Mitsuya; J S Cohen; S Broder
Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV).
Gene 1988;72(1-2):343-7.
1988: S Hayashi; S Phadtare; Jiri Zemlicka; M Matsukura; Hiroaki Mitsuya; S Broder
Adenallene and cytallene: acyclic-nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(16):6127-31.
1988: C Vidal; S Matsushita; Oscar R Colamonici; Jane Trepel; Hiroaki Mitsuya; Leonard M Neckers
Human T lymphotropic virus I infection deregulates surface expression of the transferrin receptor.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(3):984-8.
1988: Hiroaki Mitsuya; D J Looney; S Kuno; R Ueno; F Wong-Staal; S Broder
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells.
Science (New York, N.Y.) 1988;240(4852):646-9.
1988: A Surbone; Robert Yarchoan; N McAtee; M R Blum; M Maha; J P Allain; R V Thomas; Hiroaki Mitsuya; S N Lehrman; M Leuther
Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study.
Annals of internal medicine 1988;108(4):534-40.
1988: Hiroaki Mitsuya; S Broder
Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro.
AIDS research and human retroviruses 1988;4(2):107-13.
1987: G Ahluwalia; D A Cooney; Hiroaki Mitsuya; Arnold Fridland; K P Flora; Z Hao; M Dalal; S Broder; David G Johns
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.
Biochemical pharmacology 1987;36(22):3797-800.
1987: M Matsukura; K Shinozuka; G Zon; Hiroaki Mitsuya; Marvin Reitz; J S Cohen; S Broder
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(21):7706-10.
1987: Victor E Marquez; C K Tseng; James A Kelley; Hiroaki Mitsuya; S Broder; JS Roth; J S Driscoll
2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV).
Biochemical pharmacology 1987;36(17):2719-22.
1987: D A Cooney; G Ahluwalia; Hiroaki Mitsuya; Arnold Fridland; M Johnson; Z Hao; M Dalal; J Balzarini; S Broder; David G Johns
Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity.
Biochemical pharmacology 1987;36(11):1765-8.
1986: D A Cooney; M Dalal; Hiroaki Mitsuya; J B McMahon; M Nadkarni; J Balzarini; S Broder; David G Johns
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.
Biochemical pharmacology 1986;35(13):2065-8.
1986: R Yarchoan; Hong-Guang Guo; Marvin Reitz; A Maluish; Hiroaki Mitsuya; S Broder
Alterations in cytotoxic and helper T cell function after infection of T cell clones with human T cell leukemia virus, type I.
The Journal of clinical investigation 1986;77(5):1466-73.